GlassScriptPhysician profile
Matthew D Ramirez
NPI 1871768986
$752.50
in general payments reported to CMS, 2019-2025
17 companies · $318 in 2025
The $318 reported for 2025 was more than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46.44 · 2022: $22.26 · 2023: $156 · 2024: $210 · 2025: $318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $684.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $683.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $116.97 | 2024-2025 | |
| Genetix Biotherapeutics INC | $102.32 | 2024-2025 | Lyfgenia |
| Edwards Lifesciences Corporation | $97.85 | 2023 | |
| Springworks Therapeutics, INC. | $72.58 | 2025 | Gomekli |
| Csl Behring | $58.73 | 2024-2025 | Idelvion, Hemgenix |
| Alexion Pharmaceuticals, INC. | $57.78 | 2024 | Ultomiris |
| Novo Nordisk INC | $43.28 | 2019-2024 | Esperoct |
| Smith+Nephew, INC. | $36.80 | 2023 | Mba Titanium Subtalar Implant System, Hat-Trick, Integraendoscopic Gastro Release System |
| Adaptive Biotechnologies Corporation | $31.98 | 2025 | Clonoseq |
| Biomarin Pharmaceutical INC. | $24.63 | 2024 | Roctavian |
| Novartis Pharmaceuticals Corporation | $24.11 | 2019 | |
| Octapharma USA, INC. | $22.26 | 2022 | |
| Agios Pharmaceuticals, INC. | $21.83 | 2024 | Pyrukynd |
| Sobi, INC | $21.06 | 2023 | |
| Stryker Corporation | $20.32 | 2025 | Prostep Mica |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.